Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03749187 · ClinicalTrials.gov registry record · Phase 1
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
A Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 11
- Study locations
NCT03749187 is a Phase 1 study of Glioblastoma and Recurrent Glioblastoma that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 78 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (28% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT03749187, a Phase 1 study of Glioblastoma and Recurrent Glioblastoma, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 11
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.
Conditions Studied
Interventions
- DRUG Temozolomide (TMZ)
- DRUG PARP Inhibitor BGB-290
Study Locations (11)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
Connecticut
- Yale University - New Haven
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center - Hackensack
North Carolina
- Duke University Medical Center - Durham
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-04-03 |
| Est. Completion | 2029-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03749187
The ClinicalTrials.gov registry entry for NCT03749187 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (28% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide (TMZ) is the first listed.
NCT03749187 reports 11 study locations spanning 10 distinct geographic areas - top geographies include California, Connecticut, Maryland.
Frequently Asked Questions
What is clinical trial NCT03749187 about?
NCT03749187 is a clinical study titled "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas". This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell gro...
What is the current status of trial NCT03749187?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2019-04-03. Estimated completion is 2029-07-30.
What conditions does trial NCT03749187 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Malignant Glioma, Low Grade Glioma, WHO Grade III Glioma.
What interventions are being tested in trial NCT03749187?
The interventions under investigation include: Temozolomide (TMZ) (DRUG), PARP Inhibitor BGB-290 (DRUG).
Who is sponsoring clinical trial NCT03749187?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03749187 being conducted?
This trial has 11 study locations across California, Connecticut, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.